We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
InVitria Announces Launch of Recombinant Albumin for Diagnostics
Product News

InVitria Announces Launch of Recombinant Albumin for Diagnostics

InVitria Announces Launch of Recombinant Albumin for Diagnostics
Product News

InVitria Announces Launch of Recombinant Albumin for Diagnostics


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "InVitria Announces Launch of Recombinant Albumin for Diagnostics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

InVitria’s Recombinant Albumin-DX eliminates safety concerns, stabilizes sensitive biomarkers and enhances diagnostic performance by improving specificity, according to company.

Addressing product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products.

InVitria’s Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA).

The advantages of Recombinant Albumin-DX include:

Reduce non-specific binding and improve specificity;

• Improved consistency due to recombinant manufacturing;

• Improved stabilization of sensitive proteins and biomarkers; and

• Reduce occupational safety risk and regulatory burden of handling human or animal blood products.

Customer testing has shown that Recombinant Albumin-DX (Lipid-Free) increased biomarker activity to levels twice as high as the current commercial alternative.

In addition, stability over time was significantly improved with Recombinant Albumin-DX (Lipid-Free). Tests have also shown the bioequivalence of the Recombinant Albumin-DX to native human serum albumin (HSA).

“InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise,” said the company’s President and CEO Scott Deeter. “Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek.”
Advertisement